17:15 EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelf Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

LONDON, February 28, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a ...

NASDAQ:VRTX opened at $459.00 on Thursday. The stock has a market capitalization of $118.21 billion, a price-to-earnings ratio of -230.65, a PEG ratio of 1.80 and a beta of 0.41.

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session.

Vertex Pharmaceuticals (VRTX) is scheduled to report earnings on May 5, 2025. The last reported earnings were for reported on February 10, 2025 for Q4.